Iovance Biotherapeutics Inc (IOVA)

[jondoeuk]

WindMIL Therapeutics use marrow instead of tumour infiltrating lymphocytes. Their NSCLC trial (NCT04069936) just passed standalone safety (n=3) and now is proceeding to be combined with Opdivo (n=20) in patients who are refractory to, or have relapsed on, an anti-PD-1-containing regimen. Also, being run at Moffitt in addition to a handful of other locations.